BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 29164965)

  • 1. The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Patnaik MM
    Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
    Lam SSY; Leung AYH
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FLT3 mutations in AML: review of current knowledge and evidence.
    Daver N; Schlenk RF; Russell NH; Levis MJ
    Leukemia; 2019 Feb; 33(2):299-312. PubMed ID: 30651634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.